Endoscopic Management of Upper Urinary Tract Urothelial Carcinoma: Oncologic Outcomes and Prognostic Factors in a Contemporary Cohort
Por:
Sanguedolce, F, Fontana, M, Turco, M, Territo, A, Lucena, JB, Cortez, JC, Vanacore, D, Meneghetti, J, Gallioli, A, Gaya, JM, Redorta, JP, Breda, A
Publicada:
1 nov 2021
Ahead of Print:
1 jun 2021
Resumen:
Introduction: Appropriate risk stratification and complete tumor ablation are the key factors to optimize the oncologic outcomes of patients undertaking endoscopic management for upper urinary tract urothelial carcinoma (UTUC). We aimed to identify risk factors associated to tumor recurrence and progression in a contemporary cohort of patients diagnosed and treated with the latest endourologic technologies. Patients and Methods: Forty-seven patients were selected between January-2015 and March-2019 for an endoscopic management of UTUC. Last generation of digital ureteroscopes with image-enhancing technologies were used for the detection of the lesions. The retrograde approach was the most frequent access (n = 45/47). The confocal laser endomicroscopy and multiple biopsy devices were variably used according to site and tumor presentation for their characterization. Holmium and Thulium lasers were variably used, with their combination being the preferred approach in case of larger lesions. Primary endpoints included the identification of factors associated with UTUC recurrence and progression, and bladder tumor recurrence. Results: Median follow-up (FU) was 24 months (interquartile range 17-44). On multivariate analysis, bladder cancer (BC) recurrence was associated to previous contralateral UTUC (hazard ratios: 5.08 confidence interval [95% CI: 1.35-18.94], p < 0.05) and tumor size (hazard ratios: 1.07 [95% CI: 1.00-1.14], p < 0.05). UTUC recurrence was associated to incomplete clearance after primary treatment (hazard ratios: 4.99 [95% CI: 1.15-21.62], p < 0.05), while UTUC progression was significantly related to the number of UTUC recurrences (hazard ratios: 3.10 [95% CI: 1.27-7.53], p < 0.05). No significant survival differences in BC/UTUC recurrence, as well as in UTUC progression, were detected between risk groups. No Clavien-Dindo grade >2 were detected; one patient developed ureteric stricture at 7-month FU. Limitations involve retrospective nature of the study and relatively small number of patients. Conclusions: The appropriate use of latest technology may enhance the oncologic outcomes of the endoscopic management of UTUC without compromising the safety of the approach. Among the prognostic factors identified in our series, UTUC recurrence seems to be associated to disease progression.
Filiaciones:
Sanguedolce, F:
Univ Autonoma Barcelona, Fundacio Puigvert, C Cartagena 340-350, Barcelona 08025, Spain
Univ Sassari, Dipartimento Sci Med, Sassari, Italy
Fontana, M:
Univ Autonoma Barcelona, Fundacio Puigvert, C Cartagena 340-350, Barcelona 08025, Spain
Turco, M:
Univ Autonoma Barcelona, Fundacio Puigvert, C Cartagena 340-350, Barcelona 08025, Spain
Territo, A:
Univ Autonoma Barcelona, Fundacio Puigvert, C Cartagena 340-350, Barcelona 08025, Spain
Lucena, JB:
Univ Autonoma Barcelona, Fundacio Puigvert, C Cartagena 340-350, Barcelona 08025, Spain
Cortez, JC:
Univ Autonoma Barcelona, Fundacio Puigvert, C Cartagena 340-350, Barcelona 08025, Spain
Vanacore, D:
Univ Autonoma Barcelona, Fundacio Puigvert, C Cartagena 340-350, Barcelona 08025, Spain
Meneghetti, J:
Univ Autonoma Barcelona, Fundacio Puigvert, C Cartagena 340-350, Barcelona 08025, Spain
Gallioli, A:
Univ Autonoma Barcelona, Fundacio Puigvert, C Cartagena 340-350, Barcelona 08025, Spain
Gaya, JM:
Univ Autonoma Barcelona, Fundacio Puigvert, C Cartagena 340-350, Barcelona 08025, Spain
Redorta, JP:
Univ Autonoma Barcelona, Fundacio Puigvert, C Cartagena 340-350, Barcelona 08025, Spain
Breda, A:
Univ Autonoma Barcelona, Fundacio Puigvert, C Cartagena 340-350, Barcelona 08025, Spain
|